IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3788
Positioning
Market Dominance
Finance, Insurance, And Real Estate
Trading
$76M
Kendall Larsen
VirnetX Holding Corporation provides secure domain name registry and GABRIEL Connection Technology. The company also offers War Room software that offers safe and secure video conferencing meeting environment where sensitive communications and data is invisible to those not authorized to view it. It serves domain infrastructure and communication service providers, and system integrators.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$SII SPROTT INC. | 75 | 91 | 87 | 98 | - | - | 15.7% | 12.8% | 48.9% | 37.0% | 28.8% | 14.9% | 2.5% | 0.0x | $1.1B | VS | |
$PUK PRUDENTIAL PLC | 73 | 88 | 97 | 80 | - | - | 13.2% | 1.4% | 100.0% | 97.0% | 23.8% | 11.8% | 2.7% | 5.0x | $21.5B | VS | |
$NMR NOMURA HOLDINGS INC | 72 | 81 | 92 | 87 | - | - | 9.9% | 0.6% | 84.5% | 70.0% | 7.3% | 14.9% | 0.0% | 923.0x | $18.3B | VS | |
$PSLV Sprott Physical Silver Trust | 69 | 82 | 80 | 98 | - | - | 17.3% | 17.7% | 100.0% | 100.0% | 100.0% | 1643.8% | 0.0% | 0.0x | $5.0B | VS | |
$UFCS UNITED FIRE GROUP INC | 68 | 81 | 93 | 76 | 5.0x | 3.5x | 13.2% | 4.1% | 99.9% | 14.7% | 11.1% | 9.2% | 2.1% | 16.0x | $775M | VS | |
$SLF SUN LIFE FINANCIAL INC | 68 | 83 | 95 | 63 | - | - | 12.6% | 0.9% | 32.0% | 31.3% | 7.9% | -12.9% | 4.3% | 24.0x | $37.8B | VS | |
$CBOE Cboe Global Markets, Inc. | 68 | 75 | 63 | 77 | 21.3x | 15.7x | 24.0% | 13.7% | 41.7% | 32.4% | 26.4% | 8.2% | 1.1% | 30.0x | $25.7B | VS | |
$PHYS Sprott Physical Gold Trust | 67 | 64 | 82 | 91 | - | - | 22.5% | 22.8% | 101.8% | 100.0% | 100.0% | 138.9% | 0.0% | 0.0x | $8.4B | VS | |
$VTMX Vesta Real Estate Corporation, S.A.B. de C.V. | 67 | 69 | 77 | 80 | - | - | 8.8% | 5.8% | 98.7% | 75.7% | 88.5% | 17.6% | 4.3% | 34.0x | $2.2B | VS | |
$GLDM World Gold Trust | 66 | 54 | 85 | 92 | 11.3x | 11.3x | - | 27.1% | 100.0% | 98.9% | 459.9% | 333.4% | 0.0% | 0.0x | $43.7B | VS | |
$VHC VirnetX Holding Corp | 38 | 29 | 14 | 75 | - | - | -52.9% | -40.8% | 100.0% | -78524.5% | -68996.8% | 5700.0% | 0.0% | 30.0x | $76M | ||
| SECTOR BENCH | - | - | - | - | - | 11.9x | 7.8x | 8.9% | 1.2% | 76.5% | 17.0% | 21.5% | 10.8% | 1.9% | 0.5x | - | REF |
VirnetX Holding Corp (VHC) receives a "Avoid" rating with a composite score of 37.9/100. It ranks #3788 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Kendall Larsen
Chief Executive Officer
Labor Force
20
29
21
27
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for VHC
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Finance, Insurance, And Real Estate sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for VHC.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 29 | 26 | +3NEUTRAL |
| MOMENTUM | 75 | 83 | -8DRAG |
| VALUATION | 14 | 2 | +12ALPHA |
| INVESTMENT | 21 | 7 | +14ALPHA |
| STABILITY | 27 | 18 | +9ALPHA |
| SHORT INT | 21 | 7 | +14ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -52.9% (sector 8.9%)
GM 100% vs sector 77%, OM -78525% vs sector 17%
Capital turnover N/A, R&D intensity 3412.3%
Rev growth 5700%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags VirnetX Holding Corp with an Avoid rating, assigning a composite score of 37.9/100 and 1 out of 5 stars. Ranked #3788 of 7,333 stocks, VHC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
VHC's quality score of 29/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -52.9% (sector avg: 8.9%), gross margins of 100.0% (sector avg: 76.5%), net margins of -68996.8% (sector avg: 21.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
VHC registers a value score of just 14/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 2.59x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
VirnetX Holding Corp's investment score of 21/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 5700.0% vs. a sector average of 10.8% and a return on assets of -40.8% (sector: 1.2%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
VHC shows strong momentum characteristics with a score of 75/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 5700.0% year-over-year, while a beta of 0.56 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
VHC's stability score of 27/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.56 and a debt-to-equity ratio of 30.00x (sector avg: 0.5x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
VirnetX Holding Corp's short interest score of 21/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 30.00x), micro-cap liquidity risk. At $76M (micro-cap), VHC carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
VirnetX Holding Corp is a micro-cap company in the Finance, Insurance, And Real Estate sector, ranked #0 of 50 in its sector (100th percentile) and #3788 of 7,333 overall (48th percentile). Key comparisons include ROE of -52.9% trailing the 8.9% sector median and operating margins of -78524.5% below the 17.0% sector average. This top-quartile standing reflects exceptional competitive strength relative to Finance, Insurance, And Real Estate peers.
While VHC currently exhibits a AVOID profile, superior opportunities exist within the FINANCE, INSURANCE, AND REAL ESTATE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Finance, Insurance, And Real Estate Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (14) would have the largest impact on the composite score.
ROE 692% BELOW SECTOR MEDIAN
Gross Margin 31% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 461466% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate VirnetX Holding Corp (VHC) as Avoid with a composite score of 37.9/100 at a current price of $14.47. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (75th percentile) and quality (29th percentile), which together account for the majority of the composite score. Offsetting weakness in value (14th percentile) and investment (21th percentile) tempers our overall conviction. We assign a No Moat rating (37/100), High uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
VirnetX Holding Corp holds a top-quartile position (#0 of 50) within the Finance, Insurance, And Real Estate sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.9/100 places it at rank #3788 in our full 7,333-stock universe. At $76M in market capitalization, VirnetX Holding Corp is a small-cap player in the Finance, Insurance, And Real Estate space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 5700% and momentum in the 75th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 21th percentile indicates reinvestment patterns that investors should monitor for sustainability.
The margin cascade tells an important story: gross margins of 100% (+23.5pp vs sector) narrow to operating margins of -78525% (-78541.5pp vs sector) and net margins of -68996.8%, yielding a gross-to-net conversion rate of -68997%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $14.47, VirnetX Holding Corp is trading at a premium to fundamental value. Our value factor score of 14/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 2.6x, P/S of 702.7x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 5700% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Positive momentum (75th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Avoid rating (composite 37.9/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -68996.8% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to VirnetX Holding Corp. Key risk factors include current negative profitability (net margin -68996.8%), below-average price stability (27th percentile), weak quality scores (29th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -68996.8%); below-average price stability (27th percentile); weak quality scores (29th percentile); low beta of 0.56 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 27th percentile and quality factor at the 29th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate VirnetX Holding Corp's capital allocation as Poor. Key concerns include low returns on equity (-52.9%), negative profitability, weak asset returns (ROA -40.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — VirnetX Holding Corp significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, VirnetX Holding Corp receives a Avoid rating with a composite score of 37.9/100 (rank #3788 of 7,333). Our quantitative framework assigns a No Moat (37/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on VirnetX Holding Corp at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign VirnetX Holding Corp a meaningful economic moat, scoring 37/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12/20.
The strongest moat sources are margin superiority (12/20) and growth durability (11.2/20). GM 100% vs sector 77%, OM -78525% vs sector 17%. Rev growth 5700%, 10yr history. These pillars form the core of VirnetX Holding Corp's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and financial resilience (6.8/20). ROE proxy -52.9% (sector 8.9%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect VirnetX Holding Corp's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, robust top-line growth of 5700% expanding the revenue base. The margin cascade from 100% gross to -78525% operating to -68996.8% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 29th percentile.
The margin profile shows gross margins of 100%, operating margins of -78525%, net margins of -68996.8%. Return metrics include ROE of -52.9% and ROA of -40.8%. Relative to the Finance, Insurance, And Real Estate sector, gross margins are 23.5 percentage points above the sector median of 77%, and ROE of -52.9% compares to a sector median of 8.9%.
The balance sheet reflects moderate leverage with D/E of 30%, revenue growth of 5700%. The sector median D/E is 0%, putting VirnetX Holding Corp at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (29th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081
We can readily understand why investors are attracted to unprofitable companies. For example, VirnetX Holding...

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. Fluor posted adjusted earnings of 68 cents per share, beating market estimates of 57 cents per share. The company’s quarterly sales came in at $3.82 billion versus expectations of $4.11 billion. Fluor shares declined 7.7% to $38.84 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers TRxADE HEALTH, Inc. (NASDAQ: MEDS) shares jumped 214% to $13.00. TRxADE HEALTH announced the sale of assets of subsidiary Trxade, Inc. to Micro Merchant Systems for $22.5 million, with potential additional $7.5 million payout. AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) surged 203% to $0.6487. AgriFORCE was granted patent from the USPTO related to its FORCEGH+ facilities. Monopar Therapeutics Inc. (NASDAQ: MNPR) shares jumped 170% to $0.9130. Monopar received clearance to proceed with first-in-human Phase 1 trial of novel radiopharmaceutical MNPR-101-Zr in advanced cancers. Biofrontera Inc. (NASDAQ: BFRI) gained 125% to $1.69. Biofrontera announced restructuring of supply agreement with Biofronter AG. Biofrontera also announced a $16 million private placement. Biotricity, Inc. (NASDAQ: BTCY) rose 72.7% to $1.59. Shineco, Inc. (NASDAQ: SISI) shares climbed 71.8% to $2.5232 after surging more than 16% on Friday. Shineco recently announced plans for a 1-for-10 reverse stock split to regain compliance with Nasdaq minimum bid requirement. SciSparc Ltd. (NASDAQ: SPRC) gained 52.7% to $5.32. SciSparc reported that as part of its ongoing collaboration with Clearmind Medicine, Clearmind filed three patent applications under the international Patent Cooperation Treaty. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares rose 37% to $12.55. WuXi Advanced Therapies announced Tuesday that the U.S. Food and Drug Administration (FDA) approved it to begin analytical testing and manufacturing of AMTAGVI for Iovance Biotherapeutics at its Philadelphia site. AMTAGVI received accelerated approval of its BLA on Feb. 16. Iovance also ...

Gainers Auddia Inc. (NASDAQ: AUUD) shares rose 103.2% to $0.8809 in pre-market trading after gaining around 9% on Friday. Infobird Co., Ltd (NASDAQ: IFBD) shares surged 69.1% to $2.46 in pre-market trading. Infobird recently regained compliance with Nasdaq minimum bid price requirement. Chinook Therapeutics, Inc. (NASDAQ: KDNY) gained 66.8% to $40.01 in pre-market trading after the company agreed to be acquired by Novartis AG. DatChat, Inc. (NASDAQ: DATS) gained 50.8% to $0.6101 in pre-market trading after gaining 8% on Friday. Micromobility.com Inc. (NASDAQ: MCOM) shares rose 22.2% to $0.2811 in pre-market trading. Tenax Therapeutics, Inc. (NASDAQ: TENX) shares climbed 16.2% to $0.38 in pre-market trading. Tenax Therapeutics recently announced it received a Notice of Allowance from the USPTO for its patent application covering the use of TNX-103 in pulmonary hypertension with heart failure with preserved ejection fraction. AIM ImmunoTech Inc. (NYSE: AIM) shares gained 11.6% to $0.56 in pre-market trading after jumping 10% on Friday. Advanced Health Intelligence Ltd. ...

Gainers Getaround, Inc. (NYSE: GETR) shares surged 112% to $0.7020 in pre-market trading. Getaround acquired substantially all assets of HyreCar for an aggregate purchase price of $9.45 million. Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares rose 35.2% to $2.61 in pre-market trading after the company highlighted recent corporate progress, and reported financial results for the first quarter. Blue Bird Corporation (NASDAQ: BLBD) shares gained 30% to $25.16 in pre-market trading after the company reported better-than-expected Q2 results. Rubicon Technologies, Inc. (NYSE: RBT) shares rose 19.5% to $0.5340 in pre-market trading after dropping around 15% on Thursday. Momentus Inc. (NASDAQ: MNTS) shares gained 18.5% to $0.4979 in pre-market trading following Q1 results. Babylon Holdings Limited (NYSE: BBLN) shares climbed 16% to $1.38 in pre-market trading after dropping 42% on Thursday. Babylon recently reported mixed Q1 financial results. The company also announced it secured financing and plans to implement a ...

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. ClearOne, Inc. (NASDAQ: CLRO) climbed 66.1% to $2.06 after the company announced a special one-time cash dividend of $1.00 per share of common stock, payable May 31 to shareholders of record on May 22, 2023. Ensysce Biosciences, Inc. (NASDAQ: ENSC) gained 52.8% to $5.26 after the company announced completion of PF614-MPAR-101, a clinical study examining its first pain medication with overdose protection, PF614-MPAR. Mobiquity Technologies, Inc. (NASDAQ: MOBQ) climbed 48.5% to $0.2302 after gaining around 7% on Monday. Novavax, Inc. (NASDAQ: NVAX) shares climbed 46.4% to $10.91 after the company reported mixed Q1 financial results and issued FY23 revenue guidance above estimates. Neuronetics, Inc. (NASDAQ: STIM) gained 37.3% to $3.02 after the company reported better-than-expected Q1 sales results, issued Q2 guidance and raised FY23 total worldwide revenue guidance. Shengfeng Development Limited (NASDAQ: SFWL) rose 26.7% to $5.62. Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) climbed 25.6% to $8.51 following upbeat Q1 results. VirnetX Holding Corporation (NYSE: VHC) surged 25.5% to $0.44 after the company announced a partnership with Samsung. Tivic Health Systems, Inc. (NASDAQ: TIVC) gained 25.4% to $0.1630. Tivic Health, on Monday, launched a B2B portal. Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares rose 22.1% to $10.15 after reporting a profit for the first quarter. Rover Group, Inc. (NASDAQ: ROVR) gained 18.8% to $4.80 following strong quarterly results. Palantir Technologies Inc. (NYSE: PLTR) surged 17.8% to $9.12 after the company reported strong Q1 results and said it expects to remain profitable each quarter through the end of the year. Aris Water Solutions, Inc. (NYSE: ARIS) gained 17.5% to $8.47 following better-than-expected quarterly results. Vivid Seats Inc. (NASDAQ: SEAT) rose 17.1% to $9.24 after the company reported better-than-expected Q1 sales results and raised FY23 revenue guidance above estimates. Maris-Tech Ltd. (NASDAQ: MTEK) gained 17% to $0.9805 after the company announced it entered into an agreement with Art of Logic Australia for $7.5 million of a new product based on the company's Uranus-AI product. ERYTECH Pharma S.A. (NASDAQ: ERYP) rose 17% to $1.03 after the company provided a business and financial update for Q1. NeoGenomics, Inc. (NASDAQ: NEO) ...